CTOs on the Move

Vitro Biopharma

www.vitrobiopharma.com

 
Vitro Biopharma, a publicly traded biotechnology firm (OTCQB:VODG), develops technology and products derived from adult stem cells and is currently focused on mesenchymal stem cells (MSCs). MSCs have numerous applications in treatment of a variety of medical conditions, including injuries or diseases of the joints, heart, kidney, liver and lung failure, MS, stroke, cancer, hearing loss, and various other regenerative medicine applications. MSCs may be derived from an individual patient, expanded and then transplanted back to that patient to treat injury or disease through regeneration or repair of specific cells. Vitro manufactures and distributes to global markets a series of ...
  • Number of Employees: 25-100
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

LamdaGen Corp

LamdaGen Corp is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Expansion Therapeutics

Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases.

Quench Bio

Quench Bio is a biotechnology company leveraging new insights into gasdermin biology and innate immunity to develop medicines for severe inflammatory diseases.

ARCA biopharma

ARCA was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. ARCA`s lead development program is intended to be a direct implementation of those ideas. Gencaro™ (bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation (AF). ARCA has identified genetic variations in cardiac receptors that we believe may predict individual patient response to Gencaro™, giving Gencaro™ the potential to be the first genetically-targeted prevention treatment for AF. ARCA is also developing rNAPc2 as potential treatment for RNA-associated diseases, initially focused on COVID-19.

Ikaria

Ikaria is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.